Search research articles
Contact Us
Filters
Showing results (441-450 of 501) with videos related to
Page
of 51
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2016
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
Page
of 51
Search research articles
Search
Showing results (441-450 of 501) with videos related to
Sort By:
Page
of 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2016
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
Page
of 51